Hareth Nahi, MD, of the Karolinska Institutet, Stockholm, Sweden, discusses the association between drug cost and toxicity at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. In multiple myeloma (MM), he uses the example of carfilzomib and bortezomib. While carfilzomib yields fewer side effects, it is more expensive. Dr Nahi explains how the cost of treating drug side effects, combined with the increased quality of life associated with carfilzomib, makes it the clear drug of choice.
Drug cost vs. toxicity in MM
